Despite recent advances in early detection and treatment, breast cancer remains a common and devastating health problem. With the advent of molecularly-targeted therapeutics, biomarkers that are associated with biological subtypes of cancer may be useful for predicting responses to therapeutic interventions.
Researchers at the Biodesign Institute of Arizona State University and collaborators have identified 28 antigens as potential biomarkers for the early detection of breast cancer. These biomarkers were selected out of 6500 tumor antigens in a sequential screening study and yielded supporting evidence in a blinded validation study.
These biomarkers may be critical components of diagnostic tests and personalized therapeutics for breast cancer.
- Diagnostic tests to detect breast cancers
- Monitoring of breast cancer treatment
- Components of personalized breast cancer therapy
Benefits and Advantages
- Potentially the first strong biomarkers for breast cancer
For more information about the inventor(s) and their research, please see
Dr. LaBaer's laboratory webpage
Dr. Anderson's laboratory webpage